cartazolate cartazolate cartazolate (sq-65,396) is a drug of the pyrazolopyridine class. it acts as a gabaa receptor positive allosteric modulator at the barbiturate binding site of the complex and has anxiolytic effects in animals. it is also known to act as an adenosine antagonist at the a1 and a2 subtypes and as a phosphodiesterase inhibitor. cartazolate was tested in human clinical trials and was found to be efficacious for anxiety but was never marketed. it was developed by a team at e.r. squibb and sons in the 1970s. not to be confused with tracazolate. cartazolateclinical dataroutes ofadministrationby mouthatc codenonelegal statuslegal status in general: uncontrolled identifiers iupac name уthyl 4-(butylamino)-1-ethyl-1h-pyrazolopyridine-5-carboxylate cas number34966-41-1pubchem cid37015chemspider33966unii8k93z46wpychemblchembl8184comptox dashboard (epa)dtxsid20188511 chemical and physical dataformulac15h22n4o2molar mass290.367 g·mol−13d model (jsmol)interactive image smiles o=c(c1=cn=c(n(cc)n=c2)c2=c1ncccc)occ synthesis cartazolate and etazolate synthesis condensation of aminopyrazole (1) with diethyl ethoxymethylenemalonate (2) gives the product of the addition-elimination (3). the product tautomerizes spontaneously to the hydroxypyridine (4). the hydroxyl group is then converted to the chloro-derivative by means of phosphorus oxychloride (5). displacement of halogen by n-butylamine gives the antidepressant compound cartazolate. displacement of halogen by the basic nitrogen of acetone hydrazone affords the antidepressant etazolate.